On April 6, Ohio Governor Mike DeWine signed Executive Order 2022-05D to suspend the normal rulemaking process to allow the State of Ohio Board of Pharmacy to classify a number of bezimidazole-opioids as Schedule One drugs, meaning they have no accepted medical use in treatment and pose an imminent hazard to public health, safety, and welfare.
In This Issue
- National Conference Delegate Applications Due May 9
- Register by April 15 for Chief Resident Workshop
- Family Physician Author Shares Insight on Culture of Wellness – Join Us!
- Request for Peer Reviewers of New OAFP Initiative
- The OAFP Receives AAFP Membership Award
- Black Maternal Health Week April 11-17
- ODH Provides COVID Vaccine Incentives for Medicaid Members
- Applications Open for AAFP Vaccine Science Fellowship
- Black Women in Ohio 2.2 Times More Likely to Die from Pregnancy-Related Causes, Data Shows
- Module 3 of OhioRISE Community and Provider Training April 29
- Minority Health Month: Spotlight on the Center for Diversity and Health Equity
- OhioRISE Community and Provider Module 2 Training Recording Now Available
- U.S. Senate Passage of COVID Bill Unlikely
- House Bill 616 Introduced
- Governor Signs Executive Order Effectively Banning New Opioids
- Good Friday/Easter COVID-19 Vaccine Deliveries
- Adult COVID-19 Vaccine Ancillary Kit Changes
- Surprise Billing Portal Goes Live
- New COPD Resources Available from AAFP
- Medicare Sequestration Begins
- Newborn Safety Incubator Rules Set For Refiling
Comments
Leave a Comment
Your email address will not be published. Required fields are marked *